|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >> |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page 1 of 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
One of the biotech laggards of the year, Medivation (NASDAQ: MDVN) saw a very high volume selloff (
Glucose is one of the most important chemical structures because it is essential in providing the body with energy. It is integral in the chemical process called aerobic respiration, which generates a usable form of energy. Glycolysis is the beginning of this process, which oxidizes glucose to form CO2, H20, and adenosine triphosphate (ATP).
Questcor Pharmaceuticals (NASDAQ: QCOR) was one of the most heavily shorted stocks on the NASDAQ according to the most rece
This morning, Northwest Biotherapeutics (NASDAQ: NWBO) announced the initiation of a 60-patient Phase I/II trial at the MD Anderson Cancer Center for the newest version of their personalized cancer immunotherapy DCVax-Direct – here is the press release (
The recent doubling of shares of Clovis Oncology (NASDAQ: CLVS) after the company’s presentation at ASCO 2013 still leaves many biotech investors baffled at the market’s new, intrinsic ~$1.9 B valuation of the company’s early-stage oncology pipeline compounds CO-1686 and Rucaparib, although continuing analysis of the data seems to be supporting the new CLVS market cap quite nicely.
Yesterday, Biogen Idec (NASDAQ: BIIB) was the worst performer amongst the larger pharmaceutical companies after Cowen analyst Eric Schmidt pointed that that the IMS prescription sales data for new prescriptions (NRx) of the company’s recently launched multiple sclerosis / MS drug Tecfidera (dimethyl fumarate) may be flawed due to double counting of patients were prescribed a new dose of the drug.
Login Form
BioMedReports
Healthcare Review: ACADIA Pharmaceuticals, Chembio Diagnostics, STAAR Surgical, GenMark Diagnostics, Arena Pha... http://t.co/oQkwRxU8ce
BioMedReports
Medivation’s Xtandi Threatened by J&J’s New Acquisition: One of the biotech laggards of the year, Medivation (... http://t.co/VwmG4D0XY3